公开(公告)号：US20250042921A1

公开(公告)日：2025-02-06

申请号：US18413444

申请日：2024-01-16

Applicant: Quanta Therapeutics, Inc.

Inventor： Hong LIN ,  Juan LUENGO ,  Neil JOHNSON ,  Audrey HOSPITAL

IPC: C07D519/00

Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II) (II*) (III) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants.

公开(公告)号：US20230374042A1

公开(公告)日：2023-11-23

申请号：US18362576

申请日：2023-07-31

Applicant: Quanta Therapeutics, Inc.

Inventor： Hong LIN ,  Juan LUENGO ,  Neil JOHNSON ,  Audrey HOSPITAL

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (II*), (III) or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants.

公开(公告)号：US20240199650A1

公开(公告)日：2024-06-20

申请号：US18503626

申请日：2023-11-07

Applicant: Quanta Therapeutics, Inc.

Inventor： Hong LIN ,  Juan LUENGO ,  Neil JOHNSON ,  Audrey HOSPITAL ,  Jin ZENG

IPC: C07D519/00 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  C07D487/08

CPC classification number: C07D519/00 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  C07D487/08

Abstract: Provided herein are compounds, such as compounds of Formula (I), Formula (I-A), Formula (I-B), or pharmaceutically acceptable salts of any one there, useful for modulating KRAS GD12 and/or other G12 mutants.

公开(公告)号：US20240327356A1

公开(公告)日：2024-10-03

申请号：US18482674

申请日：2023-10-06

Applicant: QUANTA THERAPEUTICS, INC.

Inventor： Hong LIN ,  Juan LUENGO

IPC: C07D239/26 ,  A61P35/00 ,  C07D403/04 ,  C07D403/14

CPC classification number: C07D239/26 ,  C07D403/04 ,  C07D403/14 ,  A61P35/00

Abstract: The disclosure provides pyrimidine based derivatives of Formula (I), (I-a), (I-b), (I-c), (I-d), (II), or (III), or salts thereof, for the modulation of Ras/Raf signaling. In another aspect, the present disclosure provides methods for the modulation of Ras/Raf signaling using pyrimidine based derivatives of Formula (I), (I-a), (I-b), (I-c), (I-d), (II), or (III), or salts thereof.

公开(公告)号：US20250051365A1

公开(公告)日：2025-02-13

申请号：US18892208

申请日：2024-09-20

Applicant: Quanta Therapeutics, Inc.

Inventor： Hong LIN ,  Juan LUENGO ,  Audrey HOSPITAL ,  Jin ZENG ,  Pei GAN

IPC: C07D519/00 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/554 ,  A61K31/675 ,  C07D487/04 ,  C07D487/08 ,  C07D495/10 ,  C07D495/20 ,  C07F9/6561

Abstract: Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (I-A), (I-B), (I-C), (I-C*), (I-D), (I-E), (I-F), (I-G), (I-H), (I-I), (I-J), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any one thereof. The compounds provided herein are useful for modulating KRAS GD12 and/or other G12 mutants.